Aclaris Therapeutics, Inc. (ACRS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.61-1.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ACRS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 348.3% |
| Our one-year growth estimate | diamond | -31.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 379.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
ACRS — debt issuance
Dated 2026-10-27
Entry into a Material Definitive Agreement. On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the underwriters (the “Underwriters”) listed therein, to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share (“Common Stock”) and pre-funded warrants to purchase 6,500,000 shares o…
Why it matters: The results will show if Aclaris's second antibody works for atopic skin disease. The trial enrolled 109 patients.
Watch forTop-line results meet the trial's main goal and show a clear benefit over placebo.
Also watch forTop-line results miss the main goal or show no clear benefit over placebo.
Why it matters: A start would advance the company's planned study in a disease it says has no approved treatments. The plan calls for two study parts.
Supportive ifAclaris or a trial registry confirms Part A of the ATI-2138 Phase 2b study has begun by the end of 2026.
Worry ifPart A has not begun by the end of Q1 2027, or Aclaris delays or drops the study.
Why it matters: Aclaris reported about $204.6 million in cash at September 30, before a large share and warrant sale. The next filing can show how funding plans changed.
Watch forThe next filing reports cash above $204.6 million and keeps the stated runway through 2028.
Also watch forThe next filing reports cash below $204.6 million and no longer states that funds cover operations through 2028.
Why it matters: A trial start would move ATI-052 beyond small Phase 1b studies. The company named EoE as its first Phase 2b focus.
Supportive ifA company update or trial registry lists the ATI-052 Phase 2b EoE study as started by early 2027.
Worry ifThe study has not started by the end of Q1 2027, or Aclaris delays or drops the EoE plan.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $791 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,985 loss on $10,000 · 49.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: An IND filing is the next stated step before human testing can begin. A delay would push back this program's first clinical study.
Supportive ifAclaris announces that it filed the ATI-9494 IND with the FDA by December 31, 2026.
Worry ifAclaris has not filed the IND by December 31, 2026, or announces a delay.
Why it matters: The Phase 1b results showed activity in both skin disease and asthma. A second trial plan would test how far the program may expand.
Watch forAclaris names a second ATI-052 disease and gives a trial plan with a start window.
Also watch forAclaris says it will focus only on EoE, or gives no second-disease plan by the next earnings update.